Compass plots a course to phase III with $80M B round for psilocybin in resistant depression April 28, 2020 By Cormac Sheridan No Comments DUBLIN – Compass Pathways Ltd. raised $80 million in a series B round to continue its development of the psychedelic drug psilocybin in treatment-resistant depression.Read More